High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
Tabrizi
S J
SJ
Department of Neurodegenerative Disease, Institute of Neurology, and National Hospital for Neurology and Neurosurgery, London, UK.
Blamire
A M
AM
Manners
D N
DN
Rajagopalan
B
B
Styles
P
P
Schapira
A H V
AH
Warner
T T
TT
D000284:Administration, Oral; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000097:blood; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D003401:Creatine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D009483:Neuropsychological Tests; D010349:Patient Compliance; D010725:Phosphocreatine / Q000097:blood; D010865:Pilot Projects; D016896:Treatment Outcome; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D010725:Phosphocreatine; D001224:Aspartic Acid; C000179:N-acetylaspartate; D003404:Creatinine; D003401:Creatine